Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Huahui Health Launches Novel Libevitug (HH-003) for Treatment of Chronic Hepatitis D Virus Infection
Huahui Health has introduced a novel investigational drug candidate, Libevitug (HH-003), aimed at treating chronic hepatitis D virus (HDV) infection. This anti-PreS1 human monoclonal antibody is designed to target and neutralise both hepatitis B virus (HBV) and HDV.
Syndax Launches Revuforj® for Relapsed/Refractory Acute Leukemia Treatment
Syndax Pharmaceuticals has launched Revuforj® (revumenib), the first and only menin inhibitor for treating relapsed or refractory (R/R) acute leukaemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and paediatric patients aged one year and older.
Johnson & Johnson Unveils First and Only Nipocalimab for the Treatment of Sjögren’s disease
Johnson & Johnson has introduced nipocalimab as the first investigational therapy for adults with moderate-to-severe Sjögren’s disease (SjD), a chronic autoimmune condition affecting approximately four million people globally, predominantly women.
Fresenius Kabi Launches Tyenne®, the First Tocilizumab Biosimilar
Fresenius Kabi has launched its tocilizumab biosimilar, Tyenne®, which references Actemra®** (tocilizumab), making it the first and only tocilizumab biosimilar available in Canada.
Hansoh Pharmaceutical Group Introduces Breakthrough B7-H3-Targeted Antibody-Drug Conjugate (ADC) HS-20093
Hansoh Pharmaceutical Group has announced that its B7-H3-targeted antibody-drug conjugate (ADC), HS-20093, has received approval for breakthrough therapy designation from the National Medical Products Administration (NMPA) of China.
Ultragenyx Pharmaceutical Developed First-of-its-kind Setrusumab (UX143) for Osteogenesis Imperfecta
Ultragenyx Pharmaceutical has developed setrusumab (UX143), a groundbreaking treatment aimed at reducing the fracture risk associated with osteogenesis imperfecta (OI) Types I, III, or IV in patients aged 2 years and older.
Boehringer Ingelheim Discovered Novel Survodutide for the Treatment of Advanced Fibrosis
Boehringer Ingelheim has identified a novel treatment known as survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist, for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis (stages 2 or 3).
Arrowhead Pharmaceuticals Develops Novel Plozasiran
Arrowhead Pharmaceuticals has developed plozasiran (formerly ARO-APOC3), a novel investigational therapy designed to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Genentech Unveils First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech has unveiled Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), making it the first and only PD-(L)1 inhibitor available as a subcutaneous (SC) injection in the United States.
Johnson & Johnson Develops Novel RYBREVANT® for EGFR-Mutated Advanced Lung Cancer
Johnson & Johnson has introduced a groundbreaking therapy, RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib), for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or exon 21 L858R substitution mutations.
